Search results
Results from the WOW.Com Content Network
The screening glucose challenge test (sometimes called the O'Sullivan test) is performed between 24 and 28 weeks, and can be seen as a simplified version of the oral glucose tolerance test (OGTT). No previous fasting is required for this screening test, [53] in contrast to the OGTT. The O'Sullivan test involves drinking a solution containing 50 ...
The glucose tolerance test was first described in 1923 by Jerome W. Conn. [4]The test was based on the previous work in 1913 by A. T. B. Jacobson in determining that carbohydrate ingestion results in blood glucose fluctuations, [5] and the premise (named the Staub-Traugott Phenomenon after its first observers H. Staub in 1921 and K. Traugott in 1922) that a normal patient fed glucose will ...
Second-trimester ultrasound screening for aneuploidies is based on looking for soft markers and some predefined structural abnormalities. Soft markers are variations from normal anatomy, which are more common in aneuploid fetuses compared to euploid ones. These markers are often not clinically significant and do not cause adverse pregnancy ...
About Prequel Myriad’s Prequel Prenatal Screen with AMPLIFY technology has been shown to increase the level of fetal DNA 2.3-fold on average 2, allowing the test to provide pregnant patients with genetic insights into fetal development and the health of the pregnancy as early as eight weeks. The prenatal cfDNA screen can assess if a pregnancy ...
This is a shortened version of the seventh chapter of the ICD-9: Diseases of the Circulatory System. It covers ICD codes 259 to 282. The full chapter can be found on pages 215 to 258 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The triple test, also called triple screen, the Kettering test or the Bart's test, is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities (and neural tube defects). The term "multiple-marker screening test" is sometimes used instead.
The comprehensive metabolic panel, or chemical screen (CMP; CPT code 80053), is a panel of 14 blood tests that serves as an initial broad medical screening tool. The CMP provides a rough check of kidney function, liver function, diabetic and parathyroid status, and electrolyte and fluid balance, but this type of screening has its limitations.